SEC Form 4 · accession 0001209191-16-106010
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 3:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2016 | M | 5,130 | $35.35 | A | 274,425 | D | |
| Common StockF2,F3 | Mar 2, 2016 | S | 700 | $91.19 | D | 273,725 | D | |
| Common StockF3,F4 | Mar 2, 2016 | S | 3,900 | $91.82 | D | 269,825 | D | |
| Common StockF3,F5 | Mar 2, 2016 | S | 530 | $92.50 | D | 269,295 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common Stock | holding | — | — | — | 118,689 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $35.35 | Mar 2, 2016 | M | 5,130 | D | — | Jul 19, 2016 | Common Stock | 5,130 | 92,350 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $91.19 (range $90.38 to $91.35).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $91.82 (range $91.38 to $92.36).
- F5Open market sales reported on this line occurred at a weighted average price of $92.50 (range $92.46 to $92.56).
- F6Fully vested.